Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on the OVATION 2 Study with GEN-1 in advanced ovarian cancer patients.

Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating Runway LAWRENCEVILLE, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN)

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Data Maturity at Issue Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Aug.

LAWRENCEVILLE, N.J , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA

Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the Trial LAWRENCEVILLE, N.J. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an

Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for Long-Term, Repeat Administration Up To 6 Months LAWRENCEVILLE, N.J.

LAWRENCEVILLE, N.J. , July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Company’s next steps.

Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion to Conduct a Thorough Analysis of the Unblinded Study Data Before Making a Final Determination Conference Call

LAWRENCEVILLE, N.J , June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the second pre-planned interim safety

Lawrenceville, NJ , June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds of $9.3 million , after deducting